Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market

Executive Summary

The third IL-17 inhibitor on the US market will have a $3,500/month list price. But in a crowded, safety-conscious space like psoriasis, it's unclear how low the discounted price will need to go and whether competitive pricing would be enough to sway prescribers.


Related Content

Bausch Health Rises From Valeant's Simmering Ashes
Valeant Claims Progress, Asks Investors For Patience
Novartis Champions Cosentyx With More Long-Term Psoriasis Data
Valeant Sees Sunshine On Cloudy Day, But Dermatology Recovery Just Starting
LEO Pharma Gets EU Go-Ahead For Psoriasis Latecomer Brodalumab
Siliq Probably Isn't The Light At The End Of Valeant's Tunnel
Psoriasis Drug Valuation By ICER May Undercut Routine Step Therapy
Suicide Warnings For Valeant’s Siliq Could Hinder Access To Psoriasis Treatment
Congress Already Impacting Industry Drug Pricing Abuses, Valeant Says
New Interleukin Inhibitors May Give Stelara A Run For The Psoriasis Money


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts